GlassScriptPhysician profile
Ailisa Hipp Smith
NPI 1356479828
$6,002.09
in general payments reported to CMS, 2019-2025
50 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $714 · 2021: $251 · 2022: $755 · 2023: $666 · 2024: $911 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,869.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $503.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $495.17 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $377.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $376.42 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $368.69 | 2019-2025 | Otezla, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.88 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $246.31 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Sanofi-Aventis U.S. LLC | $217.52 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $212.58 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.29 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.24 | 2021-2025 | |
| Dexcom, INC. | $134.21 | 2022-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $101.76 | 2019-2025 | Ajovy |
| Abbott Laboratories | $92.51 | 2022-2025 | Freestyle Libre 3 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ailisa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.